Validation and meaningful change thresholds for an objective cough frequency measurement in chronic cough

This analysis examined the relationship between 24-hour cough frequency and cough-specific patient-reported outcomes in patients with refractory or unexplained chronic cough who were enrolled in a Phase 2b study of the P2X3-receptor antagonist gefapixant. Within the study, objective cough frequency was measured over a period of 24 hours using the Vitalograph VitaloJAK ambulatory acoustic recording device.